Intravenous immunoglobulin therapy for neuromuscular disorders

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Treatment of specific immune-mediated neuromuscular disorders involves consideration of many factors including severity of illness, concurrent medical problems, supportive therapies, and immune-modulating therapies. Many immune-modulating therapies are available, including steroids, an increasing number of immunosuppressive drugs, plasmapheresis, and intravenous immunoglobulin (IVIG). Deciding on which immune-modulating therapy involves selecting from those with proven efficacy for a specific disorder and global considerations of which therapies are most appropriate for an individual patient's circumstances. IVIG has become a commonly used therapy as it is well tolerated, easily administered, and is often efficacious with a relatively rapid action. IVIG has become a first-line therapy for several immune-mediated demyelinating polyneuropathies and may play a role in treating exacerbations of myasthenia gravis and selected chronic treatment-refractory cases of Lambert-Eaton myasthenic syndrome, dermatomyositis, and polymyositis.

Original languageEnglish (US)
Pages (from-to)340-346
Number of pages7
JournalSeminars in Neurology
Volume27
Issue number4
DOIs
StatePublished - Sep 1 2007

    Fingerprint

Keywords

  • Chronic inflammatory demyelinative polyneuropathy
  • Dermatomyositis
  • Guillain-Barré syndrome
  • Intravenous immunoglobulin
  • Lambert-Eaton myasthenic syndrome
  • Multifocal motor neuropathy
  • Myasthenia gravis
  • Neuromuscular disorders
  • Polymyositis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this